NVDA+0.84%AAPL−2.51%GOOGL−1.17%MSFT−2.04%AMZN−0.15%TSM+2.85%SPCX−1.20%AVGO+0.21%
StockVS

NASDAQ · Diagnostics & Research · USD

Adaptive Biotechnologies Corporation (ADPT) Stock Analysis

Adaptive Biotechnologies Corporation (ADPT) is a Diagnostics & Research stock listed on NASDAQ and quoted in US Dollar.

ADPT

$24.28

−$0.29 (−1.18%)

Sep 4, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare ADPT with… →

ADPT Key Statistics

As of Sep 4, 2026
Trading
Open
$24.06
Previous Close
$24.57
Day's Range
23.94–24.40
52-Week Range
12.00–26.87
Volume
1.40M
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
2.10
Valuation
Market Cap
$3.87B
P/E Ratio
unprofitable
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
12.58
EPS (ttm)Profit attributable to each share over the last twelve months.
−0.40
Financials (FY)
Revenue (FY)
$276.98M+54.77%
Net Income (FY)
−$59.50M
Profit marginThe share of revenue left as profit after all costs and taxes.
−20.73%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
159.60M
1-Year Return
+86.48%
Dividend and dates
Earnings Date
November 4, 2026estimated
Avg Volume
2.92M

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

ADPT Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)+49.51%
2025+170.89%
2024+22.35%
2023−35.86%
2022−72.77%
2021−52.55%
2020+97.63%
2019 (partial year)−25.76%

As of September 4, 2026.

ADPT Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$276.98M−$59.50M−21.5%
2024$178.96M−$159.49M−89.1%
2023$170.28M−$225.25M−132.3%
2022$185.31M−$200.19M−108.0%
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$276.98M$205.62M−$57.12M−$59.50M−21.5%
2024$178.96M$106.88M−$155.34M−$159.49M−89.1%
2023$170.28M$94.72M−$201.61M−$225.25M−132.3%
2022$185.31M$127.40M−$200.19M−$200.19M−108.0%

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

ADPT Valuation vs Diagnostics & Research Median

Median of 49 stocks
MetricADPTDiagnostics & Research medianvs median
P/S ratio12.584.99152% above
Profit margin−20.73%0.00%20.7 pts below

Medians across 49 Diagnostics & Research stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Recent News

All 11 articles ↓

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

The market values Adaptive Biotechnologies Corporation (ADPT) at $3.87B. The company sits in the Healthcare sector, in the Diagnostics & Research industry. Headcount on file is 624.

The most recent close on file for ADPT is $24.28, dated September 4, 2026. That is −$0.29 (−1.18%) against the previous close. Over the past 52 weeks the price has ranged from $12.00 to $26.87. The latest close sits 102.33% above that 52-week low.

Financial Health

Fiscal 2025 revenue came to $276.98M. That is +54.77% against the prior fiscal year, when revenue was $178.96M. The same year closed with a net loss of $59.50M. Profit margin runs at −20.73%. That is 20.7 percentage points below the Diagnostics & Research median of 0%. Trailing earnings per share are −0.4.

Across the 4 fiscal years on file, revenue moves from $185.31M in 2022 to $276.98M in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

The record shows negative trailing earnings, so no price-to-earnings ratio is published. The price-to-sales ratio is 12.58. On price-to-sales that is 152.05% above the Diagnostics & Research median of 4.99. 49 Diagnostics & Research companies report these metrics, and the medians quoted come from that group.

The reported beta is 2.1. Annualized volatility over the trailing 7 years is 75.84%. Over the trailing twelve months the price has returned +86.48%. Measured over 5 years, that is −9.28% a year compounded.

Growth & Income

No dividend is on file for ADPT.

Across the complete calendar years on file, 2025 returned +170.89% and 2022 returned −72.77%. Of the 6 complete calendar years on file, 3 finished higher. So far in 2026 the price is +49.51%.

Peer Comparison

Adaptive Biotechnologies Corporation (ADPT) operates in the Diagnostics & Research industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Adaptive Biotechnologies Corporation ADPT $3.87B —
Thermo Fisher Scientific Inc. TMO $226.94B 33.0
Danaher Corporation DHR $145.98B 37.0
Natera, Inc. NTRA $47.31B —

The Diagnostics & Research industry average P/E ratio is 33.1x. Adaptive Biotechnologies Corporation has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of September 4, 2026.

Related Diagnostics & Research Stocks

TMO

Thermo Fisher Scientific Inc.

$226.94B

 DHR

Danaher Corporation

$145.98B

 NTRA

Natera, Inc.

$47.31B

 IQV

IQVIA Holdings Inc.

$44.07B

 A

Agilent Technologies, Inc.

$42.54B

 IDXX

IDEXX Laboratories, Inc.

$42.18B
View all Diagnostics & Research stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.02T

 JNJ

Johnson & Johnson

$663.28B

 ABBV

AbbVie Inc.

$453.19B

 MRK

Merck & Co., Inc.

$370.89B

 UNH

UnitedHealth Group Incorporated

$356.47B
View all Healthcare stocks →

About Adaptive Biotechnologies Corporation

Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunosequencing platform which combines a suite of proprietary chemistry, computational biology, and machine learning to generate clinical immunomics data to decode the adaptive immune system. It provides clonoSEQ diagnostic test which detects and monitors the remaining number of cancer cells that are present in a patient's body during and after treatment, known as Minimal Residual Disease (MRD). The company offers products and services for life sciences research, clinical diagnostics, and drug discovery applications. The company was formerly known as Adaptive TCR Corporation and changed its name to Adaptive Biotechnologies Corporation in December 2011. Adaptive Biotechnologies Corporation was incorporated in 2009 and is headquartered in Seattle, Washington.

Visit website →